- Vivus conserves cash as Qsymia continues to flounder
- What do the Eisai cuts mean for Belviq?
- Orexigen rises as Contrave launches in tough obesity market
- Will Firing Leif Save Arena?
- Executive Profile: Luciano Rossetti, chief cartographer for Merck Serono's R&D roadmap
- PROFILE: How Bayer UK chief Alex Moscho pairs romanticism with realism